STAT3 and hepatocellular carcinoma: These indicate the feasibility of STAT3 inhibition with OPB-111077 but more trials are essential for assessing its safety, pharmacokinetics and therapeutic efficacy in larger cohorts of patients with HCC or other cancer types.